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ABSTRACT
Dementia, including Alzheimer’s disease (AD), is a major disorder 
causing visual problems in the elderly population. The pathology of 
AD includes the deposition in the brain of abnormal aggregates of 
β-amyloid (Aβ) in the form of senile plaques (SP) and abnormally 
phosphorylated tau in the form of neurofibrillary tangles (NFT). A 
variety of visual problems have been reported in patients with AD 
including loss of visual acuity (VA), colour vision and visual fields; 
changes in pupillary response to mydriatics, defects in fixation and 
in smooth and saccadic eye movements; changes in contrast sensi-
tivity and in visual evoked potentials (VEP); and disturbances of 
complex visual functions such as reading, visuospatial function, and 
in the naming and identification of objects. Many of these changes 
are controversial with conflicting data in the literature and no ocular 
or visual feature can be regarded as particularly diagnostic of AD. 
In addition, some pathological changes have been observed to affect 
the eye, visual pathway, and visual cortex in AD. The optometrist 
has a role in helping a patient with AD, if it is believed that signs 
and symptoms of the disease are present, so as to optimize visual 
function and improve the quality of life.  
(J Optom 2009;2:103-111 ©2009 Spanish Council of Optometry)
KEY WORDS: Alzheimer’s disease; dementia; ocular and visual featu-
res; pathology of the eye and visual cortex.
RESUMEN
Las distintas formas de demencia, entre las que se incluye la enfer-
medad de Alzheimer (EA), son graves trastornos que causan proble-
mas visuales en las personas de edad avanzada. La patología de la EA 
incluye la acumulación en el cerebro del péptido β-amiloide (Aβ en 
forma de placas seniles (PS) y de proteína tau anormalmente fosfori-
lada en forma de ovillos neurofibrilares (ONF). Se ha documentado 
un amplio espectro de problemas visuales en pacientes con EA, 
entre los que se incluye la pérdida de agudeza visual (AV), proble-
mas relacionados con la visión de color y el campo visual, cambios 
en la respuesta pupilar ante midriáticos, problemas de fijación así 
como movimientos oculares sacádicos y de seguimiento anormales; 
cambios en la sensibilidad al contraste y en los potenciales evocados 
visuales (PEV); y alteraciones de algunas funciones visuales com-
plejas, tales como la lectura, la función visuoespacial, y a la hora 
de nombrar y de identificar objetos. Muchos de estos cambios no 
están exentos de cierta controversia, puesto que en la literatura apa-
recen datos contradictorios al respecto y, además, no hay ninguna 
característica visual u ocular en la que se pueda basar el diagnóstico 
de la EA. Además, se ha observado que algunos de los cambios 
patológicos que aparecen en la EA afectan al ojo, a la vía óptica y al 
córtex visual. El optometrista juega un papel destacado a la hora de 
ayudar a los pacientes que padecen EA. Si se sospecha que existen 
signos y síntomas de la enfermedad, la ayuda en la optimización de 
la función visual contribuirá para mejorar su calidad de vida.   
(J Optom 2009;2:103-111 ©2009 Consejo General de Colegios de 
Ópticos-Optometristas de España)
PALABRAS CLAVE: enfermedad de Alzheimer; demencia; característi-
cas oculares y visuales; patología del ojo; córtex visual.
INTRODUCTION
A significant part of current optometric practice is direc-
ted to the visual problems of the elderly and this trend is 
likely to continue, given the demographic increase in the 
geriatric community worldwide. A major disorder causing 
visual problems in the older population is dementia and 
especially Alzheimer’s disease (AD), which is the commonest 
form of dementia to affect the elderly.1
AD is a degenerative disorder of the nervous system 
affecting approximately 10% of individuals aged 65 or 
over. It is estimated that 24.3 million individuals worldwide 
have dementia, with 4.6 million new cases recorded every 
year.2 There have been various estimates of the prevalence 
of AD in the elderly population.2,3 With advancing age, the 
prevalence of the disease increases to an estimated 19% in 
individuals aged 75-841, and is 30-35% for those older than 
85 years.2 The development of dementia involves a decline 
in short-term memory, impairment of judgment, and a loss 
of emotional control. These symptoms begin insidiously, 
develop slowly over a period of years, and result ultimately 
in the complete breakdown of the mental function. A small 
proportion of cases of AD (<5%) have a genetic origin, but 
most cases occur sporadically within the population.4
AD is a clinical diagnosis and during the early stages of 
the disease it can be difficult to distinguish it from other 
forms of dementia such as Pick’s disease (PiD) or dementia 
with Lewy bodies (DLB), as well as from dementias asso-
ciated with a known specific cause, such as normal pressure 
hydrocephalus, vascular disease, viral infection, or exposure 
to drugs. Despite the difficulties, however, the final suc-
cess rate in the clinical diagnosis of AD is usually quoted 
to be 75-90%.5 The clinical diagnosis of AD is based on 
criteria developed originally by the ‘National Institute of 
Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s Disease and Related Disorders Association’ 
(NINCDS-ADRDA) work group6 and modified by the 
National Institute on Aging (NIA) - Reagan Institute.7 The 
definitive diagnosis of AD, however, requires examination 
of brain tissue either by means of a biopsy or post-mortem. 
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The pathology of AD includes the deposition in the brain of 
abnormal aggregates of β-amyloid (Aβ) in the form of senile 
plaques (SP) and abnormally phosphorylated tau in the 
form of neurofibrillary tangles (NFT) (Figure 1). Significant 
densities of SP and NFT in the cerebral cortex of the brain 
are required for a pathological diagnosis of AD. There are no 
treatments that can arrest the progression of AD, but some 
drugs can successfully treat the symptoms for a period of 
time. 
AD can also affect the eye, visual pathway, and visual 
cortex and result in various visual signs and symptoms. 
Because of the increasing numbers of elderly people in the 
population, the optometrist is likely to see elderly patients 
in their practice, some of whom will have or will be develo-
ping AD, and is expected to have a role in managing their 
visual symptoms.8 Hence, this review describes the general 
pathology of AD, the ocular and visual features that have 
been described, and the pathological changes in the visual 
system that may explain these symptoms. The literature 
search began with several of the major reviews of the topic 
dating from 1989-19967,9-12 and then proceeded to examine 
specific changes in AD from 1996 to the present as compiled 
by PUBMED and ISI Web of knowledge.
PATHOLOGY OF ALZHEIMER’S DISEASE (AD)
General Features
AD is characterized by a large number of pathological 
changes affecting the brain. Few of these changes are specific 
to AD, however, and many appear to be exacerbations of 
normal aging.13 There is atrophy of the cerebral hemispheres 
with narrowed gyri and widened sulci and widening of the 
subarachnoid space.14 These gross changes mainly affect the 
frontal, temporal, and parietal lobes and often spare the 
occipital lobe. The meninges are thickened by fibrosis and 
the ventricles are often dilated.15 The white matter appears 
yellow and ‘rubbery’ and there is ‘spongiosis’ (development 
of vacuolation) and ‘gliosis’ (a proliferation of glial cells 
which is often associated with pathological changes in the 
brain) affecting the grey matter.15 These changes may be 
more apparent in cases of early onset (<65 years) while some 
late-onset cases (>65 years) may exhibit little atrophy.16
Histological Features
Ever since the first descriptions of pre-senile dementia 
by Alois Alzheimer in 1907,17 the formation of SP and NFT 
(Figure 1) have been regarded as the defining histological fea-
tures of Alzheimer’s disease (AD).7,18,19 AD formally became 
recognized as a disease entity in 1910 and was named after 
Alzheimer by Kraepelin, based on the clinical and patholo-
gical description of the original cases. The most important 
molecular constituent of the SP is β-amyloid (Aβ)20 and, 
consequently, SP are also referred to as Aβ deposits. Several 
types of Aβ deposits have been identified in AD brains, 
but the majority can be classified into three morphological 
subtypes:21,22 1) diffuse deposits, in which most of the Aβ 
peptide is not aggregated into fibrils and dystrophic neurites 
and paired helical filaments (PHF) are infrequent or absent, 
2) primitive deposits, in which the Aβ is aggregated into 
amyloid and dystrophic neurites and PHF are present, and 
3) classic deposits, in which Aβ is highly aggregated to form 
a central ‘core’ surrounded by a ‘ring’ of dystrophic neurites. 
The latter type of deposit is especially common in the visual 
cortex.23,24
The most important molecular constituent of the NFT 
is the microtubule-associated protein (MAP) tau, which 
is involved in the assembly and stabilization of the micro-
FIGURE 1
Neuropathology of Alzheimer’s disease: A. β-amyloid (Aβ) deposits in the form of senile plaques (SP) in a section of the cerebral cortex. 
Deposits appear as brown patches and are widely distributed, especially in the cerebral cortex (β-amyloid immunohistochemistry), B. neu-
rofibrillary tangles (NFT) in the cerebral cortex appearing as inclusion bodies within neurons (tau immunohistochemistry).
A B
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tubules and, therefore, establishes and maintains neuronal 
morphology.25,26 In normal neurons, tau is soluble and binds 
reversibly to microtubules with a rapid turnover.27 In AD, 
however, tau does not bind to the microtubules but collects 
as insoluble aggregates to form PHF which resist proteolysis 
and accumulate as NFT. Tau extracted from AD brains con-
sists of both soluble and insoluble forms where, in the latter 
case, the tau present is in an abnormally phosphorylated 
isoform.28
PATHOGENESIS OF AD 
Studies of the molecular composition of Aβ deposits and 
NFT have played an important role in the development of 
hypotheses as to the pathogenesis of AD. For example, the 
discovery of Aβ as the most important molecular constituent 
of the SP20 led to the development of the ‘Amyloid Cascade 
Hypothesis’ (ACH), the most important model of the mole-
cular pathology of AD developed to date.29 The ACH propo-
ses that the deposition of Aβ is the initial pathological event 
in the disease, leading to the formation of NFT, cell death, 
and, ultimately, dementia. A number of gene mutations 
have been implicated in familial forms of AD. Rare cases are 
linked to mutations of the amyloid precursor protein (APP) 
gene on chromosome 2130,31 and a larger group to the prese-
nilin (PSEN) genes PSEN1 on chromosome 1432 and PSEN2 
on chromosome 1.33 In addition, the apolipoprotein E (apo 
E) gene on chromosome 19 is an important risk factor asso-
ciated with late-onset familial and sporadic AD,34 possession 
of one or more E4 alleles significantly increasing the risk of 
developing the disease.  
There are, however, observations that are difficult to 
reconcile with the ACH. First, in transgenic mice, genes 
over-expressing the amyloid precursor protein (APP) do 
not produce the predicted series of pathological events.35,36 
Second, SP and NFT appear to be separated in the brain 
both temporally37 and spatially,38 suggesting that the two 
lesions may develop independently. Indeed, in the entorhinal 
cortex, the NFT may actually precede the appearance of SP.36 
The uncertainty as to the significance of SP and NFT in AD 
has led to alternative models being proposed to explain the 
aetiology of AD based on perturbation of vesicular traffic-
king at synapses, disruption of the cytoskeletal network, or 
the distribution of membrane cholesterol.39
VISUAL CHANGES IN ALZHEIMER’S DISEASE
A number of visual changes have been reported in AD 
patients and these are summarized in table 1.
Visual Acuity
Visual acuity (VA) can be difficult to measure accurately 
in patients with AD during the later stages of the disease, 
but studies suggest that VA is normal in the early stages 
of the disease.40-44 Low-contrast acuity using Regan charts 
presented at four contrast levels, however, shows a reduc-
tion in acuity with contrast in AD.45 In patients in whom 
impairments of VA have already been demonstrated, there 
may be impairments in stereopsis as measured by random 
dot stereograms.46
Colour Vision
Whether or not there is defective colour vision in AD is con-
troversial, with some studies suggesting normal colour vision in 
patients with mild to moderate AD.44 In other studies, however, 
defective colour vision may be present in approximately 50% 
of patients.40,42 There is little available information on whether 
there are specific colour vision problems in AD; e.g., affecting 
the Red/Green (R/G) rather than Blue/Yellow (B/Y) axis. The 
ability to use colour information may be impaired in AD. 
Hence, in cognitive tasks in which colour is used as an attention 
enhancer, a cue, or as a distracter, patients with AD were less 
accurate in their performance than controls.44
Contrast Sensitivity
VA provides information about the ability of the patient 
to resolve higher-contrast spatial details. The contrast sen-
sitivity function (CSF), however, provides a measure of 
the performance across a wider range of spatial frequencies 
and contrasts. The performance of patients with AD is not 
clear. Some studies have not reported changes in contrast 
sensitivity in AD.43 Other studies have reported reduced 
contrast sensitivities in AD over all spatial frequencies,45,47,48 
and others at lower spatial frequencies only.49 Differences 
in reported performance may be attributable to variation 
in patient population or assessment methods and especially 
failure to account for VA differences between groups.50 
Hence, it is likely that there are contrast sensitivity changes 
in AD, but it is not possible to be specific about the fre-
quencies affected.
Critical Flicker Fusion Frequency Threshold and Visual 
Masking
The critical flicker fusion threshold, i.e., the lowest 
frequency at which the patient can no longer perceive a 
flickering light as a steady light, is normal in AD.9  Patients 
with AD often show deficits on visual masking tasks.49 Visual 
masking involves the presentation of a second stimulus 
immediately before (forward masking) or after (backward 
masking) a test stimulus. Patients with AD are significantly 
affected by a backward patterned mask stimulus compared 
with age-matched controls.51 This result suggests that the 
speed of central visual processing, which often decreases with 
age, is reduced even further in AD.
Visual Fields
There have been few studies of the visual fields in AD. 
In one report, visual sensitivity was reduced throughout the 
visual field but deficits were most pronounced in the inferior 
field.52 In addition, in follow up studies of patients with AD, 
it was found that there may be a progression of visual field 
loss over time.52 
Pupillary Function
There has been considerable interest in whether patients 
with AD exhibit an abnormal pupillary response to the 
muscarinic receptor antagonist tropicamide, widely used by 
optometrists as a mydriatic.53 Early reports suggested that 
some patients with AD display a specific response to low 
J Optom, Vol. 2, No. 3, July-September 2009 
106   Alzheimer’s Disease and the Eye: Armstrong RA
doses (typically 0.01%) of tropicamide, with pupils dilating 
at least 13% more compared with normal elderly controls.35 
However, subsequent studies suggest that the tropicamide 
test is not a reliable method of diagnosing AD. For example, 
there is no difference between the response of AD patients 
and that of patients with vascular dementia (VaD)55 or 
Parkinson’s disease.56 In addition, not all studies have shown 
a significantly different response between AD and elderly 
control patients although a difference was demonstrated 
compared with young controls.55 Hence, use of the tropica-
mide response cannot be recommended as a clinical applica-
tion to detect AD.57,58 
Enhanced pupillary responses in AD have also been 
reported following the application of dilute solutions of 
phenylephrine (a sympathetic agonist) and of pilocarpine (a 
cholinergic agonist).59 Reductions in the pupillary light reflex 
have also been reported in AD, although these responses are 
highly variable.60
Eye Movements 
The ability of some patients to fixate a target is affected 
in AD.41,42 Defects of fixation control may be associated with 
degeneration of the parietal lobe of the brain, a region belie-
ved to be involved in maintaining fixation stability. Several 
changes in saccadic eye movements have been reported. First, 
saccadic latency declines with age but the delays become 
more pronounced in patients with AD.61 Second, saccadic 
velocities are reduced, the degree of this reduction being 
correlated with the severity of the dementia. Third, patients 
at more advanced stages of the disease exhibit inaccurate sac-
cades with undershooting of the target by 10-30%.62 Fourth, 
50% of the patients with AD have difficulty in initiating or 
maintaining saccadic eye movements.62
Smooth pursuit eye movements, which are a sensitive 
indicator of brain function, may also be affected.63 A gra-
dual deterioration of these movements occurs in AD with 
catch up saccades being necessary to maintain fixation.61 
Degeneration and atrophy of the frontal and/or the parietal 
lobes may be responsible for these changes.
Electrophysiology
A number of electrophysiological changes have been 
recorded in patients with AD. First, changes in the electrore-
tinogram (ERG) have been reported in some patients but not 
TABLE 1 
Functional changes in vision in Alzheimer’s disease
Visual function Change in AD References
Visual acuity   Controversial, normal in many patients 40-45
Colour vision 50% of patients affected in some studies 40,42,44
Visual fields Few studies. Inferior visual field affected 52
Stereopsis Reduced in visually symptomatic patients 46 
Pupil dilation Controversial response to tropicamide 53-60
Fixation Affected  in some patients 41,42
Saccadic eye Delayed compared with elderly controls 41,42,61,62
Movements Delayed peak velocity. Inaccurate saccades
 50% of patients show abnormalities in
 saccadic initiation
Slow pursuit movements Impaired with intrusion of saccades 61,63
Contrast sensitivity May be a defect affecting all frequencies 43,45,47,48,50
Visual masking Significantly affected by backward masking 49,51
Critical flicker fusion Not affected 9  
Flash ERG Not affected 10,64 
Pattern ERG Reduction in wave amplitude in some patients 10,65-68
Cortical VEP  Normal P100 latency and delayed 70-74
 flash P2 latency in some studies
Visuospatial  40-50% of patients exhibit deficits  42,76,77
Reading  Problems in understanding written words 75
Object recognition 50% of patients reveal problems with object recognition 40,49
Eye-head coordination Impaired 78
Visual hallucinations 20% of patients experience visual hallucinations 82 
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in others. For example, the amplitude of the pattern-ERG 
(PERG) response is reduced, although the flash electroretino-
gram ERG may be unaffected.10,64 A significant delay in the 
N35, P50, and N95 components of the PERG, together with 
reductions in amplitude have been reported accompanied 
by significant reductions in nerve fibre layer thickness.65 In 
other studies the amplitude and latency of the components 
of the PERG have been reported to be unaffected.66-68 The 
reduction in the ‘b’ wave shown in some studies could be 
attributable to the reduced number of ganglion cells in the 
retina in AD patients.65,69 
Second, a number of studies dating from the 1980s have 
suggested that the latency of the flash P2 component of the 
cortical visual evoked response (VEP) is delayed and the 
P100 component to a reversing checkerboard is normal in 
patients with AD.70-73 This pattern of abnormalities, however, 
has not been shown in all studies and has not been adopted 
subsequently as a routine test for AD.74
Complex Visual Functions
Patients with AD exhibit difficulties with more com-
plex visual functions such as reading75, visuospatial func-
tion42,76,77 and in the identification and naming of objects.40 
Significantly greater thresholds for perceiving shapes defined 
by motion cues49 may be present and this is likely to affect 
object recognition. Patients with AD also show impairment 
of eye-head coordination,78 problems with finding objects 
when surrounded by others,79 and in finding known objects 
in an unknown environment.80 Deficient perception and 
cognition in AD are often attributed to slow information 
processing. Increasing ‘stimulus strength’ by for example 
increasing stimulus contrast can often improve various 
aspects of the cognitive performance in AD.81
In rare cases, patients develop a particular combination of 
visual symptoms called ‘Balint’s syndrome’ before any signs 
of dementia are apparent.82 These include a psychic paraly-
sis of gaze (ocular apraxia), optic ataxia (lack of muscular 
coordination) e.g., an inability to guide the hand towards 
an object using visual information, and a spatial disorder 
of attention (‘simultanagnosia’): viz., an inability to report 
all items or their relationships in pictures depicting events 
or situations.11 These symptoms are accompanied by visual 
field constriction, the fading of centrally fixated objects, and 
impaired reading ability despite normal VA. It is possible 
that these symptoms are attributable to degeneration of more 
complex visual areas rather than to retinal dysfunction or to 
problems affecting the primary visual pathway.11 
Visual Hallucinations
Visual hallucinations may be present in some patients, 
especially in those with impaired VA and with more severe 
cognitive impairment.82 Visual hallucinations, however, may 
accompany many disorders including Creutzfeldt-Jakob 
disease and DLB.82
PATHOLOGICAL CHANGES IN THE VISUAL SYSTEM
Pathological changes that have been observed in the 
visual system in AD are summarised in table 2. Pathological 
changes may occur at several sites in the visual system from 
eye to brain, and hence, the visual signs and symptoms obser-
ved in AD are likely to reflect a combination of both ocular 
and neural factors.
Changes Affecting the Eye 
Whether or not patients with AD show characteristic 
pathological changes within the eye, observable during fun-
dus investigation, is controversial. Some studies have failed 
to detect any fundus abnormalities in AD except those to be 
expected in normal aged individuals.46 Nevertheless, a pro-
portion of patients may show abnormalities including disc 
pallor, optic atrophy, and disc cupping.41 
Retinal nerve fibre layer abnormalities have been studied 
in AD and in age-matched controls using retinal photo-
graphy. A higher proportion of patients with AD exhibit 
TABLE 2 
Pathological changes in the visual system in Alzheimer’s disease
Region Change in Alzheimer’s disease References
Lens Deposition of β-amyloid 85
Retina Reduction in retinal ganglion cells,  65,69,83,84
 thinning of the nerve cell layer
Optic disc Disc pallor, optic atrophy, disc cupping in  41,46
 the absence of open-angle glaucoma in some patients   
Optic nerve Decline in nerve axons, preferentially  62,84,86 
 affecting the large-diameter axons (M cell pathway)    
Lateral geniculate nucleus Accumulation of lipofuscin,  10 
  resistant to tangle (NFT) formation  
Supra chiasmatic nucleus Degeneration reported in some patients 92
Visual cortex Rarely atrophic, myelin reduced  23,24,94,95
 in outer laminae, loss of pyramidal cells 
B17 Numerous cored senile plaques but few tangles 23,24
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abnormalities in these tests compared with controls, but 
there is often disagreement between observers as regards the 
interpretation of photographs, especially in more advanced 
cases of AD.83 Hence, it is possible that there is ganglion 
cell degeneration in AD. Consistent with this suggestion, 
significant reductions in the retinal nerve fibre layer thickness 
using optical coherence tomography have also been shown in 
a group of 17 AD cases.65
Studies of the retinae of patients with AD obtained post-
mortem suggest a reduction in the number of ganglion cells 
and in the thickness of the nerve cell layer.69 Ganglion cells 
may also be swollen or shrunken and some may contain 
vacuoles. A reactive gliosis may accompany these changes. A 
decline in the number of retinal ganglion cells could explain 
the disc abnormalities observed in some patients.84 Open-
angle glaucoma was unlikely to be the cause in these cases, 
since intraocular pressure was recorded to be less than 19 mm 
Hg in all patients, and none of the patients with AD had a 
family history of glaucoma.84 Nevertheless, low-tension glau-
coma cannot be ruled out in these patients. In addition, Aβ 
deposits may also be found in the lens of the eye in patients 
with AD.85
Changes Affecting the Visual Pathway
A well established pathological change in patients with 
AD is the decline in the density of optic nerve fibres (Figure 
2).62,84 In some studies, a preferential decline in the larger-
diameter axons has been reported,62,84 whereas in other 
studies a decline in the smaller-diameter axons may be pre-
sent.86 There may be subtypes of AD in which degeneration 
affects preferentially either the large or small axons. Whether 
this degeneration reflects a decline in retinal ganglion cells, 
degeneration of the visual cortex affecting the retina as a 
consequence of retrograde degeneration, or both is yet to be 
established. 
A decline in large-diameter axons in the optic nerve 
suggests that it is the M- rather than the P-cell pathway that 
is affected in AD. This pathway, which is stimulated using 
low contrast and luminance stimuli and by coarse patterns is 
essentially a ‘luminance’ channel involved in motion detec-
tion.87 Its specific degeneration could explain the abnorma-
lities in the cortical flash VEP that have been reported pre-
viously in some studies. Hence, some studies have suggested 
that the latency of the flash P2 component is delayed while 
the P100 component to a reversing checkerboard stimulus 
is normal in patients with AD.88-90 However, as mentioned 
above, critical flicker fusion frequency threshold is apparently 
normal in AD9 and this is also mediated by M cells. If the 
smaller-sized axons are affected in the optic nerve of AD 
patients, then the data suggest impairment of the P pathway. 
This pathway is more significantly involved in the detection 
of fine details of the visual scene and with colour vision.87 
Consistent with the involvement of the P pathway, abnor-
malities of colour vision have been observed in up to 50% of 
patients with AD.42
Degeneration of the lateral geniculate nucleus (LGN) is 
rare in AD.10 Neurons in this region are some of the most resis-
tant in the nervous system to the development of cellular NFT. 
However, cells in the LGN accumulate lipofuscin, a pigment 
found in increasing amounts in nerve cells with age.10
 Suprachiasmatic Nucleus (SCN)
The suprachiasmatic nucleus (SCN) is reported to dege-
nerate in some Alzheimer’s patients.91 This structure, located 
within the hypothalamus, receives an input from the retina 
and is involved in regulating the timing of sleep. Hence, 
degeneration of the SCN may explain the sleep disturbances 
reported in many AD patients.92
Pathology of the Visual Cortex
Although atrophy of the parietal lobe of the brain is com-
mon in AD, this rarely spreads to involve all of the occipital 
lobe. Pathological changes within the visual cortex normally 
involve the visual association areas and spare to some degree, 
the primary visual cortex (area V1). However, a number of 
pathological changes have been reported in the visual cortex 
in Alzheimer patients. In a retrospective study of 106 patients 
with AD,24  SP and NFT were observed in the visual cortex 
in 72% and 27% of cases respectively. The density of SP and 
especially NFT is generally greater in the visual association 
areas (V2, V3 etc.) than in V1 especially in younger cases. 
FIGURE 2
Cross-sections of part of the optic nerve showing the axon profiles. 
The upper picture shows axon profiles corresponding to an elderly 
control patient and the lower picture corresponds to a patient with 
Alzheimer’s disease (AD) (sections stained with toluidine blue, 
Magnification bar represents 5 μm).
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In area V1, SP with distinct amyloid cores and relatively 
few NFT can be observed while in V2, numerous uncored 
‘neuritic’ plaques and tangles are usually present.23 Whether 
differences in cortical pathology between areas V1 and V2 are 
responsible for the cortical VEP to flash and pattern stimuli 
described previously remains to be established.93 In a signifi-
cant proportion of cases of AD, the density of SP and/or NFT 
is significantly greater in the cuneal compared with the lingual 
gyrus of area V1.  This difference could contribute to the pre-
dominantly inferior visual field deficits reported in one study.52 
In addition, the amount of myelin appears to be reduced in 
the outer laminae of the visual cortex and loss of neurons and 
neurotransmitters have been reported.23
THE OPTOMETRISTS ROLE
As primary eye-care practitioners, optometrists should be 
able to identify the visual problems of patients with AD and 
should be expected to work with patients and their carers to 
manage their visual welfare.95 
In the Identification of AD
The optometrist has a role in helping a patient with AD 
if it is believed that signs and symptoms of the disease are 
present and especially if no diagnosis has yet been made. The 
symptoms of AD are highly variable; some patients not exhi-
biting any visual symptoms while others may show various 
combinations of such symptoms. In addition, the literature 
regarding the visual changes in AD is controversial, with 
different studies often giving conflicting results. In addition, 
optometrists should not use the 0.01% tropicamide test 
as a test for AD, as recent studies57,58 have not confirmed 
earlier reports.53 However, it is important that optometrists 
continue to use the regular dosage of tropicamide (1%) for 
papillary dilation and ocular health examination.
Detecting the Visual Problems of the Patient
The following tests and procedures may be useful in 
identifying the visual problems of a patient with AD. It is 
particularly important to carry out the full examination, 
including ocular health assessment. Subsequently, several 
additional tests may be helpful such as regular assessment 
of binocular vision. Hence, the ‘motility test’ should be 
carried out and the practitioner should notice whether the 
movement of the eyes is smooth and whether or not they fall 
behind the target. In addition, saccadic eye movements could 
be tested. The patient should be asked to fixate an object in 
the primary position as fixation is affected in a proportion 
of patients, the patient's eyes often drifting away from the 
target.41,42 The patient could be asked to read a page of print 
since a patient with AD is likely to have problems with this 
task and to exhibit a reduction in reading speed compared 
with normal subjects. Finally, colour vision could be tested 
monocularly and binocularly as a defect may be present in as 
many as 50% of patients.40,41 
Practical Ways the Optometrist Can Help
Patients with AD are likely to have visual problems that 
have not been detected due to the developing dementia. 
The dementia population generally is less likely to be able 
to describe their visual problems effectively and is more 
likely to experience and tolerate visual deficits.96 In a sam-
ple of 85 patients with AD in a nursing home environment, 
for example, 80 required spectacles for the correction of 
presbyopia, myopia or both.96 Of these patients, 25 had 
not actively been using spectacles since entering the nursing 
home; nine were too cognitively impaired to request them, 
eight had lost or damaged their spectacles, and eight had 
prescriptions no longer accurate enough to correct their 
vision. One factor that improves the quality of life of a 
patient with AD and that, as a consequence, reduces the 
burden on those that care for the patient, is for the patient 
to be able to see as clearly as possible. Hence, it is important 
that the visual problems present should be investigated and 
detected by the eye practitioner and those due to ocular 
factors corrected as far as possible. In addition, it is impor-
tant to bring to the attention of carers visual problems of 
the patient that cannot be corrected, such as oculomotor 
apraxia, field defects, or problems with colour vision. As a 
consequence of such information, carers can make accom-
modations for these problems, e.g., by careful use of colours 
or in the positioning of objects.
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